BR0313729A - Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo - Google Patents

Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo

Info

Publication number
BR0313729A
BR0313729A BR0313729-5A BR0313729A BR0313729A BR 0313729 A BR0313729 A BR 0313729A BR 0313729 A BR0313729 A BR 0313729A BR 0313729 A BR0313729 A BR 0313729A
Authority
BR
Brazil
Prior art keywords
estrogen
bmp
methods
responsive element
estrogen responsive
Prior art date
Application number
BR0313729-5A
Other languages
English (en)
Inventor
Peter Van Nest Bodine
Dan Gazit
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0313729A publication Critical patent/BR0313729A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"ELEMENTO RESPONDENTE A ESTROGêNIO BMP-2 E MéTODOS DE USO DO MESMO". A presente invenção refere-se a um ácido nucléico isolado correspondendo à região reguladora BMP-2, ou um fragmento da mesma, compreendendo um elemento respondente a estrogênio, vetor compreendendo o mesmo e células que compreendem, o dito vetor. Em outra concretização, a invenção proporciona métodos para identificar um agonista de estrogênio, antagonista de estrogênio e um agente terapêutico. Em outra concretização, a invenção proporciona métodos para tratar condições que são associadas com insuficiência de estrogênio ou com falta de resposta a estrogênio externo ou de agonistas do mesmo.
BR0313729-5A 2002-08-16 2003-08-18 Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo BR0313729A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40402402P 2002-08-16 2002-08-16
PCT/US2003/023271 WO2004016639A1 (en) 2002-08-16 2003-08-18 Bmp-2 estrogen responsive element and methods of using the same

Publications (1)

Publication Number Publication Date
BR0313729A true BR0313729A (pt) 2005-06-21

Family

ID=31888312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313729-5A BR0313729A (pt) 2002-08-16 2003-08-18 Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo

Country Status (14)

Country Link
US (1) US20050271637A1 (pt)
EP (1) EP1534731A4 (pt)
JP (1) JP2006500925A (pt)
KR (1) KR20050083635A (pt)
CN (1) CN1753904A (pt)
AU (1) AU2003261246A1 (pt)
BR (1) BR0313729A (pt)
CA (1) CA2497304A1 (pt)
CO (1) CO5721011A2 (pt)
MX (1) MXPA05001694A (pt)
NO (1) NO20050935L (pt)
RU (1) RU2005107330A (pt)
WO (1) WO2004016639A1 (pt)
ZA (1) ZA200502131B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005266875B2 (en) 2004-07-23 2012-07-26 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
KR20190097310A (ko) 2005-11-23 2019-08-20 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN103920139B (zh) 2007-02-01 2018-02-02 阿塞勒隆制药公司 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI459963B (zh) 2007-02-09 2014-11-11 Acceleron Pharma Inc 包含ActRIIa-Fc融合蛋白的醫藥組合物；ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途；ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK2340031T3 (da) 2008-08-14 2019-07-15 Acceleron Pharma Inc Gdf-fanger til anvendelse ved behandling af anæmi
EP3058986B1 (en) 2009-03-30 2018-05-09 Acceleron Pharma Inc. Bmp-alk3 antagonists and uses for promoting bone growth
EP2440576A4 (en) 2009-06-08 2013-11-20 Acceleron Pharma Inc PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
CN102656187A (zh) 2009-06-12 2012-09-05 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
US8501690B2 (en) 2010-04-30 2013-08-06 John G. Stark Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
EP3964224A1 (en) 2012-11-02 2022-03-09 Celgene Corporation Activin-actrii antagonists and uses for use in treating renal disease
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
SI3227675T1 (sl) 2014-12-03 2023-07-31 Celgene Corporation Antagonisti aktivin-actrii in uporaba za zdravljenje mielodisplastičnega sindroma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
JPS59500735A (ja) * 1983-04-18 1984-04-26 エス・ア−ル・アイ・インタ−ナシヨナル 人間の癌診断のための方法および試験キツト
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US6083690A (en) * 1995-06-02 2000-07-04 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents
WO1998025460A1 (en) * 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions and methods for stimulating bone growth
JPH11313673A (ja) * 1998-04-30 1999-11-16 Hoechst Marion Roussel Kk ヒトｂｍｐ−２プロモーターおよびこれを用いた骨関連物質の探索法
US6630304B1 (en) * 2000-09-14 2003-10-07 Decode Genetics Ehf. Human osteoporosis gene

Also Published As

Publication number Publication date
EP1534731A1 (en) 2005-06-01
CO5721011A2 (es) 2007-01-31
JP2006500925A (ja) 2006-01-12
KR20050083635A (ko) 2005-08-26
ZA200502131B (en) 2005-09-21
AU2003261246A1 (en) 2004-03-03
NO20050935L (no) 2005-05-10
US20050271637A1 (en) 2005-12-08
WO2004016639A1 (en) 2004-02-26
EP1534731A4 (en) 2006-05-17
RU2005107330A (ru) 2005-10-10
MXPA05001694A (es) 2005-07-22
CA2497304A1 (en) 2004-02-26
CN1753904A (zh) 2006-03-29

Similar Documents

Publication Publication Date Title
BR0313729A (pt) Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo
BR0114754A (pt) Compostos não-imidazóis
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
BR0107943A (pt) Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos
BR0209919A (pt) Composições pesticidas lìquidas estáveis
BR0207977A (pt) Métodos de combinação de inibição de crescimento tumoral com um antagonista de receptor de fator de crescimento endotelial
TR200101858T2 (tr) JNK protein kinaz inhibitörleri olarak 4-ariloksindoller
BR9806752A (pt) Ftalazinonas.
BRPI0400860A (pt) Sistema e método para facilitar perfilamento de aplicações
BR0111298A (pt) Moduladores seletivos dos receptores de andrógenos e métodos para identificação, projeto e uso dos mesmos
NO20085251L (no) Steroide sapogeninger samt deres derivater for behandling av Alzheimers sykdom
BRPI0411078A (pt) ligantes de receptores de canabinóides e seus usos
BRPI0407305A (pt) Ligantes do receptor de canabinóides e seus usos
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
BR0115715A (pt) Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
WO2004021174A3 (en) Scheduler for use in a microprocessor that supports data-speculative-execution
BR0213233A (pt) Alcinos inibidores de metaloproteinase de matriz
BRPI0410177A (pt) métodos de distribuir um ingrediente
WO2007030611A3 (en) A calculated index of genomic expression of estrogen receptor (er) and er related genes
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
HRP20080413T3 (en) Medicament for the treatment of fungal infections, particularly aspergillosis
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
DK1480627T3 (da) Fremgangsmåder til mindskelse af angiogenese
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired